NCT05139680View on ClinicalTrials.gov

A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

May 19, 2023

Study Completion Date

May 19, 2023

Conditions
Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
Interventions
DRUG

tafamidis

80 or 61 milligrams (mg)

Trial Locations (1)

10017

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY